Karen Sue Canady

Dr. Canady has been practicing in the intellectual property field since the mid-1990's.  Her practice emphasizes biotechnology patent preparation and prosecution.  She also counsels clients and prepares opinions relating to patentability, patent validity, infringement, freedom to operate, and other aspects of portfolio assessment.  Some examples of her work include developing and prosecuting a portfolio of lentiviral gene delivery patents and applications that was sold by her client for $12 million, and evaluating a portfolio of antisense molecules to help a client close a deal involving a $45 million dollar upfront licensing fee and the potential for over $230 million in milestone payments.

Her broad-ranging intellectual property experience, including a year of practicing in Europe, coupled with a background in neurobiological research, provides a solid foundation for representing and advising clients in the pursuit and evaluation of patent rights, both domestically and abroad. Her experience in intellectual property law includes patent and trademark prosecution, client counseling and litigation support. She has been a frequent speaker at professional programs, particularly on the topics of drafting patent validity and infringement opinions and biotechnology patent prosecution. Her prosecution practice has emphasized biotechnology, including diagnostic and therapeutic products and methods relating to regenerative medicine, recombinant DNA technology, vaccines, antibodies, stem cells, genomics and gene therapy.